Papyrus Advances Commercial Scale Milestone with 200 Biodegradable Samples Delivered
Papyrus Australia reached a key production milestone by delivering 200 biodegradable Collar Keeper® samples to TBS Mining Solutions, confirming its manufacturing scalability. The company’s May cash flow shows a steady funding runway amid ongoing R&D and commercialisation efforts.
- Completed Milestone 2 under TBS contract with 200 product samples
- Validated pulp performance on commercial-scale board forming lines
- Maintained steady R&D activity at Adelaide rapid prototyping facility
- Reported net operating cash outflow of AUD 172k in May
- Available funding supports approximately 5.8 months of operations
Key Contract Milestone Achieved
Papyrus Australia Ltd (ASX:PPY) marked a significant step forward in May by delivering 200 biodegradable Collar Keeper® samples to TBS Mining Solutions, fulfilling Milestone 2 of their contract. These samples were produced using virgin agricultural-waste pulp processed through Papyrus’ proprietary technology and converted into paperboard on commercial-scale equipment operated by third-party manufacturers. This marks the company’s first production-scale conversion for customer qualification, underscoring the scalability of its manufacturing pathway.
Ongoing R&D and Manufacturing Scale-Up
At its Adelaide Rapid Prototyping & R&D Facility, Papyrus maintained steady operations focused on optimising pulp furnish for high-strength board applications and producing customer evaluation materials. The facility is a critical platform for validating product performance ahead of scale-up transfer to the manufacturing facility. Concurrently, the company continued refining board specifications and validating pulp performance on commercial-scale board forming lines to align with TBS requirements.
Financial Position and Funding Outlook
The company’s Appendix 4C cash flow report for May shows a net operating cash outflow of AUD 172,000, driven by sample production, pulp processing, board conversion activities, and ongoing operational costs. Papyrus ended the month with AUD 400,000 in cash and cash equivalents, supplemented by AUD 592,000 in unused financing facilities, providing a total available funding of AUD 992,000. This supports an estimated 5.8 months of operations, although the company notes that removing one-off R&D costs extends this runway to approximately 7.5 months.
Papyrus has multiple loan and convertible note facilities in place, including a $264,000 convertible note issue with a 1% monthly interest rate and a $500,000 R&DTI secured facility. The company also maintains unsecured loans from directors and investors, some of which are subject to shareholder approval for conversion into equity. Management remains confident in its ability to secure future capital, citing past successful fundraising efforts and ongoing contract revenues.
Strategic Commercialisation Focus
With the delivery of Milestone 2 samples, Papyrus is positioned to support TBS through the next phase of product testing and acceptance. The company’s commercialisation strategy is advancing alongside manufacturing scale-up, aiming to transition from R&D to full production. The Adelaide facility and third-party manufacturing partnerships are central to this progression, validating product performance and preparing for customer-aligned production volumes.
Bottom Line?
Papyrus’ delivery of commercial-scale product samples and steady funding position set the stage for upcoming contract milestones and manufacturing scale-up.
Questions in the middle?
- Will Papyrus secure shareholder approval for loan-to-equity conversions to strengthen its balance sheet?
- How will the next phase of product testing with TBS impact contract acceptance and revenue recognition?
- What are the timelines and risks associated with scaling production from prototyping to full manufacturing?
